NCT06379217 2026-03-11
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
Clinical Trials
8 trialsNCT05562791 2026-01-07
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT04597411 2025-03-21
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Phase 1 Recruiting
NCT06044857 2025-03-12
PSMA PET Response Guided SabR in High Risk Pca
University of Texas Southwestern Medical Center
Phase 1 Recruiting
NCT03276572 2024-06-13
Phase I Trial of 225Ac-J591 in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Completed
NCT03822871 2024-03-21
A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer
Cancer Targeted Technology
Phase 1 Completed
NCT04216134 2023-06-15
68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer
City of Hope Medical Center
Phase 1 Completed
NCT04279561 2022-09-21
Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Terminated